Patients with mantle cell lymphoma experience better results when taking venetoclax and ibrutinib orally together.

Published Date: 13 Dec 2023

In 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), the combination of venetoclax and ibrutinib targeted therapy resulted in an overall remission rate and significantly improved progression-free survival (PFS).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot